Home/Pipeline/MP0317

MP0317

Solid Tumors

Phase 1Active (with Amunix/Sanofi)

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active (with Amunix/Sanofi)

Company

Molecular Partners

About Molecular Partners

Molecular Partners is a mission-driven biotech founded in 2004, focused on transforming the lives of patients with serious diseases through its innovative DARPin platform. The company has achieved clinical validation for its technology and is advancing a pipeline of next-generation oncology candidates, including tetra-specific T-cell engagers and logic-gated Switch-DARPins. Its strategy combines deep in-house R&D expertise with strategic collaborations to build a broad portfolio targeting high-unmet-need cancers.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed